Clinical trial of the Johnson & Johnson’s single dose coronavirus vaccine has good results


Notice: Undefined index: /(\PL|\A)(coronavirus vaccine)(\PL|\Z)/ui in /home/ on line 307

Early results from a Phase 1/2a clinical trial of the Johnson & Johnson’s single dose revealed that it was well tolerated and even one dose appeared to produce a strong immune response in almost all of the 800 participants. The participants in the trial developed antibodies against the virus 29 days after getting vaccinated. The vaccine is called Ad26.COV2.S.It \ uses the same technology used for Johnson & Johnson’s Ebola, Zika, HIV and RSV vaccines. The company says stricter vaccine guidelines under consideration by the US Food and Drug Administration might add to the company’s vaccine timeline.


Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases director, believes it may be late 2021 before things are back to normal. “By the time you get enough people vaccinated so that you can feel you’ve had an impact enough on the outbreak, so that you can start thinking about maybe getting a little bit more towards normality, that very likely, as I and others have said, will be maybe the third quarter or so of 2021. Maybe even into the fourth quarter,” he said. The global death toll from Covid-19 could double to two million before a successful vaccine is widely used, the World Health Organisation’s (WHO) emergencies director Michael Ryan warned.